Clinical pharmacokinetics of metformin in Australian Aboriginal and Torres Strait Islanders

A study of factors affecting the concentrations of metformin in Australian Aboriginal and Torres Strait Islanders with type 2 diabetes

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12611000935932

Enrollment

100

Registered

2011-08-31

Start date

2011-08-05

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study investigates the use of metformin in Australian Aboriginal and Torres Strait Islander patients with type 2 diabetes. The aim of this study is to compare the pharmacokinetics of metformin in Australian Aboriginal and non-Aboriginal Australians patients. It involves obtaining a medical history of the patient and asking patients about their metformin formulation, dose, dosing times and their compliance to the medication.

Interventions

Australian Aboriginal patients who are taking metformin for their type 2 diabetes are required to provide a minimum of 1 blood sample and a maximum of 6 blood samples on different occasions. There are no fixed timing period. Blood samples are used to determine metformin concentrations, glycosylated haemoglobin (HbA1c), creatinine, vitamin B12 and lactic acid concentration. The overall duration of this study is 24 months.

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

Australian Aboriginal or Torres Strait Islander patients with type 2 diabetes and taking metformin.

Exclusion criteria

Patients unable to provide informed consent to participate in the study.

Outcome results